Company Insights

OLK customer relationships

Explore interactive graphBrowse insights index

OLK customers relationship map

Olink (OLK): Customer Network and Commercial Implications

Olink sells high‑throughput proteomics platforms and reagents to academic, government and commercial research customers and monetizes through instrument sales, recurring reagent/consumable revenue and certified service partnerships that expand addressable volume without proportionally lifting fixed costs. For investors, the business combines scalable consumables margins with partner-driven service volume that de‑risks capital intensity while concentrating revenue growth in proteomics adoption. For relationship intelligence and follow-up, see https://nullexposure.com/.

How the model works in plain terms

Olink’s commercial model is a two‑pillar approach: direct sales of instruments and reagents to labs plus a network of certified service providers that operate Olink platforms on a fee‑for‑service basis for third‑party customers. That mix creates recurring consumables demand from both in‑house customers and partner labs while letting Olink scale geographic reach via certification rather than adding manufacturing footprint.

Key commercial signals and operating constraints

  • No explicit contract constraints were supplied in the source data. As a company‑level signal this absence aligns with an open partner network strategy rather than a small number of large exclusive contracts.
  • Contracting posture: Olink operates an asset‑light, partner‑centric posture—instrument sales lock in reagent streams, while certified service providers generate incremental volume without large direct capital expenditures by Olink.
  • Concentration: The listed relationships span leading academic centers, CROs and commercial labs, which signals low single‑customer concentration from the evidence available.
  • Criticality: Participation in large population projects and institutional core facilities demonstrates high technical criticality of Olink’s platform for proteomics research workflows.
  • Maturity: Adoption by established institutions (UK Biobank, major university medical centers) and commercial CROs indicates commercial market validation, even as company financials show investment‑stage margins consistent with growth phase (negative operating margins reported in TTM financials).

For direct access to relationship mapping and sourcing, visit https://nullexposure.com/.

The full relationship roll‑call (plain English, source)

Below are every customer relationship identified in the source material, each summarized in one to two sentences with its public source.

  • Erasmus Medical Center — The Human Genomics Facility at Erasmus adopted Olink Explore and became the Netherlands’ first certified Olink Explore lab, demonstrating academic validation in FY2022 (GlobeNewswire, June 16, 2022).
  • Microcoat — Microcoat is listed among Olink’s global certified service providers in a July 3, 2024 GlobeNewswire release establishing the partner network (GlobeNewswire, July 3, 2024).
  • Thermo Fisher Scientific Inc (TMO) — Baker McKenzie reported advising Olink on merger‑control matters related to its sale to Thermo Fisher, indicating a strategic transaction engagement in mid‑2024 (Baker McKenzie news, June 2024).
  • AssayGate — AssayGate appears on Olink’s published list of certified service providers, reflecting Olink’s CRO/core facility distribution strategy (GlobeNewswire, July 3, 2024).
  • Australian Genome Research Facility — Listed as a certified service provider in Olink’s global network announcement, extending Olink coverage in Australia (GlobeNewswire, July 3, 2024).
  • BioXpedia — Named in Olink’s certified service provider roster, indicating use of Olink technology in commercial service offerings (GlobeNewswire, July 3, 2024).
  • CheckImmune — Included in the certified provider list, signaling a presence in immunology‑focused service workflows (GlobeNewswire, July 3, 2024).
  • Core Facility Metabolomics and Proteomics, Helmholtz Munich — Helmholtz Munich’s core facility is a certified Olink service site, reinforcing institutional adoption in Europe (GlobeNewswire, July 3, 2024).
  • CRLB‑GMEL, Hamilton Health Sciences — CRLB‑GMEL is listed among certified providers, indicating Canadian academic/clinical adoption (GlobeNewswire, July 3, 2024).
  • Discovery Life Sciences — Discovery installed the largest commercial Olink platform in the Americas outside Olink itself and positioned as a global certified service provider, signaling major commercial scale deployment (PR Newswire, 2022).
  • Firalis Molecular Precision SA — Listed as a certified service provider, showing engagement with specialty molecular labs (GlobeNewswire, July 3, 2024).
  • Fulgent Genetics (FLGT) — Fulgent is included on the provider roster published by Olink, indicating commercial lab uptake (GlobeNewswire / Yahoo Finance, July 2024).
  • GENEWIZ from Azenta Life Sciences — GENEWIZ is named among certified providers, reflecting integration with broader sequencing and assay service chains (GlobeNewswire, July 3, 2024).
  • Immune Assessment Laboratory, Dana‑Farber Cancer Institute — Dana‑Farber’s immune assessment group is on the certified list, showing adoption within premier cancer research centers (GlobeNewswire, July 3, 2024).
  • Immune Monitoring and Cancer Omics Labs, OHSU Knight Cancer Institute — The OHSU Knight Cancer Institute labs are certified providers, signalling engagement with oncology omics programs (GlobeNewswire, July 3, 2024).
  • LIFE & BRAIN — LIFE & BRAIN is listed as a certified service provider in Olink’s network announcement (GlobeNewswire, July 3, 2024).
  • LuminoDx — LuminoDx appears in the provider list, adding diagnostics‑adjacent service capability to the network (GlobeNewswire, July 3, 2024).
  • NBCC‑HTS (Sinai Heath System) — The Sinai Health System facility (NBCC‑HTS) is included among certified sites, indicating hospital system adoption (GlobeNewswire, July 3, 2024).
  • NovogeneAIT Genomics — NovogeneAIT Genomics is a named certified provider, showing engagement with large genomics service players (GlobeNewswire, July 3, 2024).
  • Protavio — Protavio is on the certified provider list, expanding Olink presence in specialized proteomics services (GlobeNewswire, July 3, 2024).
  • Psomagen Inc — Psomagen is listed as a certified service provider, indicating collaboration with commercial genomics/proteomics service firms (GlobeNewswire, July 3, 2024).
  • Randox — Randox appears in the provider roster, reflecting CRO and diagnostics lab participation (GlobeNewswire, July 3, 2024).
  • Sampled — Sampled is named among certified partners, expanding Olink’s partner footprint (GlobeNewswire, July 3, 2024).
  • Sequanta Technologies — Sequanta is included in the certified provider list, reinforcing the network of commercial platforms (GlobeNewswire, July 3, 2024).
  • Sirona Dx — Sirona Dx is listed as a certified provider, showing Olink reach into diagnostic development labs (GlobeNewswire, July 3, 2024).
  • Source BioScience — Source BioScience appears on the provider roster across republished releases, indicating UK/European lab coverage (GlobeNewswire / Yahoo Finance, July 2024).
  • Svar Life Science — Svar is listed among certified service providers, broadening clinical assay support (GlobeNewswire, July 3, 2024).
  • Swiss Institute of Allergy and Asthma Research — This institute is named among certified partners, reflecting adoption in immune‑related research (GlobeNewswire / Yahoo Finance, July 2024).
  • Universidad CEU San Pablo, Institute of Molecular Applied Medicine Nemesio Díez (IMMA‑ND) — The IMMA‑ND institute is listed as a certified provider, representing Spanish academic adoption (GlobeNewswire, July 3, 2024).
  • Vanderbilt University Medical Center — Vanderbilt is named in Olink’s certified network, highlighting top‑tier academic research adoption (GlobeNewswire / Yahoo Finance, July 2024).
  • WuXi AppTec — WuXi AppTec appears on the certified provider list, adding major global CRO capacity to Olink’s service footprint (GlobeNewswire / Yahoo Finance, July 2024).
  • UK Biobank — Large‑scale population proteomics using Olink Explore platforms for >54,000 participants was reported, demonstrating Olink’s capacity for population and translational research projects (Technology Networks, 2022).
  • Radboud UMC (Radboudumc) — Radboudumc public commentary noted purchase of Olink Signature and Explore systems to expand in‑house proteomics and reduce per‑sample cost (Yahoo Finance / product announcements, 2021).

Bottom line for investors and operators

  • Customer mix is broad and institutionally credible: major academic centers, population cohorts and large CROs are all active Olink customers or certified partners.
  • Business model leverages instrument lock‑in and partner‑delivered volume: this creates recurring consumable revenues with distributed operational risk.
  • Key risks are execution and margin recovery: the company’s reported negative operating margins reflect growth investment; continued scale in both reagent sales and partner throughput is the primary path to profitability.

For a deeper look at partner mapping and source tracing, explore further at https://nullexposure.com/.

Join our Discord